Literature DB >> 17616501

Osteoporosis risk screening for women in a community pharmacy.

Yifei Liu1, Justin C Nevins, Kara M Carruthers, William R Doucette, Randal P McDonough, Xiaoyun Pan.   

Abstract

OBJECTIVES: To describe the development, implementation, and financial aspects of a sustainable osteoporosis screening service in a community pharmacy and report osteoporosis risk factors for women screened during the 48 months in which the screening service was in operation.
SETTING: An independent community pharmacy (Main at Locust Pharmacy Clinic) in Davenport, Iowa, beginning in 1999. PRACTICE DESCRIPTION: The osteoporosis screening service was provided by a staff pharmacist, a pharmacy resident, or a combination of a pharmacist and a resident. The service included use of the Hologic Sahara Bone Sonometer at the heel and education of the patient. Patient education consisted of a discussion of screening results, an overview of osteoporosis, and recommendations to address risk factors. PRACTICE INNOVATION: For patients who received osteoporosis screening, an overall cumulative risk score and a cumulative modifiable risk score were calculated. Patients were identified as having high (T-score <or=-1), moderate (-1 < T-score <0), or low (T-score >or=0) risk. An analysis was performed to determine the net financial gain or loss of osteoporosis screening. INTERVENTION: Osteoporosis screening service. MAIN OUTCOME MEASURES: T-score, overall cumulative risk score, cumulative modifiable risk score, and net financial gain of service.
RESULTS: A total of 444 women received the osteoporosis screening service during 48 months. More than 90% of the women had an overall cumulative risk score of at least 3, and 83.3% had at least one modifiable risk factor. According to the bone density tests, about 58% of the women were at high risk for osteoporosis and 25.7% were at moderate risk. The service had a net gain if provided by a pharmacist ($4,823.72), a resident ($8,153.72), or a combination of a pharmacist and a resident ($6,488.72).
CONCLUSION: This pharmacy-based osteoporosis screening service effectively identified patients at risk for osteoporosis and was sustainable for 48 months. Other community pharmacies are encouraged to offer similar services.

Entities:  

Mesh:

Year:  2007        PMID: 17616501     DOI: 10.1331/JAPhA.2007.05107

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  6 in total

1.  Cost analysis for the implementation of a medication review with follow-up service in Spain.

Authors:  Aranzazu Noain; Victoria Garcia-Cardenas; Miguel Angel Gastelurrutia; Amaia Malet-Larrea; Fernando Martinez-Martinez; Daniel Sabater-Hernandez; Shalom I Benrimoj
Journal:  Int J Clin Pharm       Date:  2017-04-22

2.  PACE: Pharmacists use the power of communication in paediatric asthma.

Authors:  Amanda Elaro; Smita Shah; Luca N Pomare; Carol L Armour; Sinthia Z Bosnic-Anticevich
Journal:  Int J Clin Pharm       Date:  2014-08-03

Review 3.  The impact of pharmacist interventions on osteoporosis management: a systematic review.

Authors:  M N Elias; A M Burden; S M Cadarette
Journal:  Osteoporos Int       Date:  2011-07-01       Impact factor: 4.507

4.  Ideal and actual involvement of community pharmacists in health promotion and prevention: a cross-sectional study in Quebec, Canada.

Authors:  Marie-Claude Laliberté; Sylvie Perreault; Nicole Damestoy; Lyne Lalonde
Journal:  BMC Public Health       Date:  2012-03-15       Impact factor: 3.295

Review 5.  Provision of Clinical Preventive Services by Community Pharmacists.

Authors:  Sarah E Kelling; Angela Rondon-Begazo; Natalie A DiPietro Mager; Bethany L Murphy; David R Bright
Journal:  Prev Chronic Dis       Date:  2016-10-27       Impact factor: 2.830

6.  A qualitative study of community pharmacists' opinions on the provision of osteoporosis disease state management services in Malaysia.

Authors:  Jah Nik; Pauline Siew Mei Lai; Chirk Jenn Ng; Lynne Emmerton
Journal:  BMC Health Serv Res       Date:  2016-08-30       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.